With Roche Opting Out, ArQule Uncertain On Plans For E2F Oncology Program
This article was originally published in The Pink Sheet Daily
Executive Summary
Well-capitalized biotech had planned to launch Phase I investigation of E2F molecule in 2009 before Roche’s unexpected decision.
You may also be interested in...
ArQule Signs c-Met Inhibitor, Discovery Platform Deals With Daiichi-Sankyo
Two deals bring the biotech $75 million upfront, plus research and clinical development funding.
Let The Negotiations Begin: Genentech Rejects Roche’s $44 Billion Bid
Genentech’s announcement that Roche’s $89 per share bid undervalues the biotech comes as little surprise. But how much is Roche willing to pay?
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.